Which cancer treatments can cause other cancers later in life?
Although pazopanib and sunitinib are similarly effective in patients with metastatic renal-cell cancer, pazopanib is associated with better safety and quality of life, according to a study.
What are some of the potential autonomic issues related to acute neurotoxicity from oxaliplatin?
What should nurses be aware of when administering denosumab?
One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the 5-year course, according to a new study.
Patients undergoing chemotherapy for hematologic cancers are at risk for this complication. The review can help you learn how to assess their risk.
Interim results confirmed the "unprecedented" single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.
A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
The 32-mg, single IV dose of the anti-nausea drug Zofran (ondansetron) will no longer be sold due to the potential for serious cardiac risks.
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Heart failure is relatively common in older women undergoing breast cancer treatment, but trastuzumab therapy appears to raise the risk even more.
Denosumab improved overall survival in persons with lung cancer and bone metastases more effectively than did zoledronic acid.
The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.
Gemtuzumab ozogamicin, discontinued here in 2010, reduced relapse risk and improved survival in Welsh patients with acute myeloid leukemia.
Combining a PI3K inhibitor with a PARP inhibitor may be an effective therapy for triple-negative breast cancer, researchers have determined.
Spermatogonial stem cells were used to overcome male infertility, which could help prepubertal boys rendered infertile by cancer treatments.
Opioid-induced constipation is not adequately addressed by nurse practitioners and physicians, according to research presented at the Oncology Nursing Society (ONS) Connections: Advancing Care Through Science conference.
Persons with cancer who use herbs or dietary supplements are at risk for harmful drug interactions, a new study has reiterated.
Nelfinavir, a protease inhibitor used in the treatment of HIV, has been found to inhibit the growth of HER2-positive tumors in mice.
Earlier study findings that anthracycline- or trastuzumab-based treatment for breast cancer raises the risk for heart failure and cardiomyopathy can be extended to a more general population of women.
Differences in the impact of aspirin in various forms of cancer are highlighted in two studies recently published in the oncology literature.
Abiraterone markedly prolongs survival in men with metastatic castration-resistant prostate cancer that has progressed after docetaxel therapy.
PARP inhibitors may be a novel treatment strategy for women with HER2-positive breast cancers, researchers have found.
Pazopanib is a tyrosine kinase inhibitor indicated for renal cell carcinoma and advanced soft tissue sarcoma in patients who have received prior chemotherapy.
The anti-estrogen tamoxifen appears to suppress gynecomastia and breast pain in men undergoing androgen-suppression therapy for prostate cancer.
Trastuzumab emtansine significantly improved survival in HER2-positive metastatic breast cancer compared with lapatinib plus capecitabine.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|